Clinical trial NCT00430937: Efficacy and Safety of Daptomycin Versus Vancomycin or Teicoplanin for Treatment of Complicated Skin and Soft Tissue Infections
Official title: A Multicenter, Randomized, Assessor-Blind Study to Evaluate Efficacy and Safety of Daptomycin Versus Vancomycin or Teicoplanin for Treatment of Complicated Skin and Soft Tissue Infections (cSSTI)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Skin Diseases, Infectious
Soft Tissue Infections
Keywords: Complicated Skin and Soft Tissue Infections. Daptomycin, Vancomycin, Teicoplanin
Complicated skin and soft tissue infections
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2007-02-02
Enrollment: 194
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study evaluated the efficacy and safety of daptomycin compared to vancomycin or teicoplanin for the treatment of complicated skin and soft tissue infections


Eligibility criteria: Inclusion criteria:

* Subjects with a diagnosis of cSSTI
* Infection known or suspected (based on Gram's stain) to be due, at least partially, to Gram-positive bacteria.
* Hospitalised subjects with clinical evidence of at least one of the following:I infected ulcers , major abscess. deep or extensive cellulitis, post-surgical / post-traumatic wound infection
* Presence of at least two of the following: drainage and/or discharge from the infection site, redness, swelling and/or hardened skin, heat and/or localised warmth, pain and/or tenderness to touch, presence of pus.

Exclusion criteria:

* cSSTIs of the following categories:

  * Infected burns,
  * Severely impaired arterial blood supply (such that the likelihood of amputation of the infected anatomical site is likely),
  * Decubitus ulcers,
  * Infected diabetic foot ulcers associated with osteomyelitis,
  * Infected human or animal bites, superficial infections or abscesses in an anatomic site, such as the rectal area, where the risk of anaerobic or Gram-negative pathogen involvement is high (e.g. perirectal abscess),
  * Necrotising fasciitis or gangrene,
  * cSSTI expected to require more than 14 days of intravenous antimicrobial therapy,
  * Skin and/or skin structure infection that can be treated by surgery alone,
  * Infections associated with a permanent prosthetic device that will not be removed within 2 days of study randomisation
* Subjects with documented bacteraemia at Baseline or those with shock or hypotension
* Concomitant clinically suspected or confirmed other site of infection or disorder at study entry that may interfere with the evaluations in this protocol
* Treatment with vancomycin or teicoplanin within the past 48 hours, unless administered for less than 24 hours.
* Subjects admitted to the hospital for conditions associated with rhabdomyolysis or those with an infection due to an organism known prior to study entry to be resistant to daptomycin, vancomycin or teicoplanin.
* Previously diagnosed disease of immune function. Human Immunodeficiency Virus (HIV) infected subjects without Acquired Immune Deficiency Syndrome (AIDS) may be enrolled.
* Subjects receiving oral steroids or receiving immunosuppressant drugs after organ transplant.
* Absence of purulent material for initial culture and Gram's stain. Subjects with cellulitis may be enrolled in the absence of purulent material, provided that infection with a Gram-positive organism is suspected.
* Subjects who have received more than 48 hours of any systemic antibiotic or topical antibiotic at the infection site with activity against Gram-positive pathogens, unless there is clinical evidence of treatment failure OR documented resistance in the identified Gram-positive pathogen to the previous antibiotic therapy.
* cSSTI suspected or documented as being due exclusively to Gram-negative or anaerobic organisms based on epidemiology or on direct examination of a Gram-stained specimen.
* Subjects diagnosed with pneumonia or those with severe renal impairment or hepatic disease
* Previous history of hearing loss. Other protocol defined inclusion/exclusion criteria may apply.

Primary outcomes:
measure: Clinical Success as Measured by Comparing the Participants Signs and Symptoms at the "Test of Cure" (TOC) Visit to Those Recorded at Study Baseline in the Clinically Evaluable Population.
timeFrame: Baseline to TOC Visit (7-14 days after end of treatment) up to 4 weeks
Secondary outcomes:
measure: Microbiological Efficacy Measured by the Number of Participants Achieving Bacteriological Eradication of Gram-positive Baseline Pathogens at the TOC Visit.
timeFrame: Baseline to TOC Visit (7-14 days after end of treatment) up to 4 weeks
Other outcomes:
Locations:
Study officials:
affiliation: Novartis
name: Novartis Pharmaceuticals
role: STUDY_DIRECTOR
References: